- Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
- Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
- Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
- Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
- Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
- Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting
- Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
More ▼
Key statistics
On Tuesday, Biomea Fusion Inc (BMEA:NSQ) closed at 10.98, 35.14% above the 52 week low of 8.13 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.79 |
---|---|
High | 11.39 |
Low | 10.72 |
Bid | 4.40 |
Offer | 11.31 |
Previous close | 10.98 |
Average volume | 902.10k |
---|---|
Shares outstanding | 35.89m |
Free float | 26.85m |
P/E (TTM) | -- |
Market cap | 394.07m USD |
EPS (TTM) | -3.46 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 21:15 BST.
More ▼